AZD 3102

Drug Profile

AZD 3102

Alternative Names: AZD-3102

Latest Information Update: 29 Jan 2016

Price : $50

At a glance

  • Originator Dyax
  • Developer AstraZeneca; Shire
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 22 Jan 2016 Dyax has been acquired by and merged into Shire
  • 08 Jun 2006 Preclinical development is ongoing for Alzheimer's disease
  • 06 Oct 2004 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top